Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 223

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 223
---
 license agreements without prior approval from Versitech Limited and to assign the agreements to any successor to the business related to the licenses. In the event that Acticule makes an improvement to the licensed technologies, so long as the improvement does not incorporate any licensed patents, Acticule will be the owner to such improvement, subject to a non -exclusiveroyalty -freelicense being granted back to Versitech Limited for academic and research purposes only. The exclusive license agreements shall be in effect until the expiration of all licensed patents (please refer to the patent expiration dates under “Intellectual Property”). Acticule may terminate the licenses at any time with 6 -monthwritten notice in advance. Either party may terminate the agreements upon a material breach by other party. SACT-1: A Repurposed Drug for the Treatment of Neuroblastoma Drug repurposing is a strategy for identifying new indications for approved or investigational drugs that are outside the scope of the original medical uses. It is often viewed as a lower -costmethod for drug commercialization, as it is based on already -approveddrugs (which has been proven to be safe for human use by the respective governing regulatory agency) and explores new target indications. (Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov.3, 673 – 683, 2004). 120 One of the advantages of drug repurposing is a lower development risk due to safety and toxicity, as well as other properties related to water solubility, absorption, distribution and metabolism, as the safety and CMC profiles of marketed drugs are usually well -established. Due to the same reason, the development time is also shortened because there is no need to repeat the whole spectrum of the safety assessment. As a result, the drug repurposing approach appears to be attractive due to its superior risk management, smaller capital investment and quicker financial return. (Sudeep Pushpakom, et. al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41 -58, 2019) The cost of bringing a repurposed drug is estimated to be around US$300 million, which is only one -tenthof the development cost for a new drug. (Nosengo, N. Can you teach old drugs new tricks? Nature. 534, 314 -316,